|
|
|
|
|
04.12.25 - 14:03
|
Sudo Biosciences Appoints Paul Bavier as Chief Legal Counsel (Business Wire)
|
|
|
CARMEL, Ind. & LONDON--(BUSINESS WIRE)--#TYK2--Sudo Biosciences, (“Sudo”), a biopharmaceutical company committed to designing and developing best-in-class precision TYK2 (tyrosine kinase 2) inhibitors, today announced the appointment of Paul S. Bavier, J.D., as Chief Legal Officer.
Mr. Bavier brings more than two decades of legal and executive leadership experience in the biotechnology industry, with deep expertise spanning company formation, financings, mergers and acquisitions, compliance, and public market readiness.
Before joining Sudo, Mr. Bavier served as General Counsel, Secretary and Chief Administrative Officer at HilleVax, Inc., where he was a founding member of the leadership team and helped guide the company through its initial public offering and clinical development milestones. He previously served as General Counsel at VelosBio, Inc. (acquired by Merck & Co.) and Avedro, Inc. (acquired by Glaukos Corporation), where he led corporate governance, compliance, and strategic initiatives. Ear...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
08.10.25 - 13:03
|
Glaukos to Release Third Quarter 2025 Financial Results after Market Close on October 29 (Business Wire)
|
|
|
Conference Call and Webcast Scheduled for 1:30 p.m. PTALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release third quarter 2025 financial results after the market close on Wednesday, October 29, 2025. The company's management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on October 29, 2025.
A link to the live webcast will be available on the company's website at http://investors.glaukos.com. To participate in the conference call, please dial 800-715-9871 (U.S.) or 646-307-1963 (International) and enter Conference ID 5255602. A replay will be archived on the company's website following completion of the call.
About Glaukos
Glaukos (www.glaukos.com) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing nov...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
